Bristol-Myers Squibb CoBMY
Price$61.46Intrinsic value$77.5826% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $49.2B+1.8% YoYTTM through 30 Jun 2026
Net Income $9.3BTTM through 30 Jun 2026
Free Cash Flow $11.4BTTM through 30 Jun 2026

Margins

Current
EBITDA Margin30.7%
Operating Margin24.2%
Net Margin18.9%

Returns

41.6%ROE
10.6%ROA
16.4%ROIC

Balance Sheet Health

Debt / Equity1.92x
Current Ratio1.53x
Net Debt$34.1B
Cash & Equivalents$8.7B

Quality Metrics

Altman Z-Score2.64
Piotroski F-Score7 / 9
FCF Margin23.3%
Rule of 4024.6
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $48.2B
Diluted EPS$4.54TTM
'19'20'21'22'23'24'25
FY2025: $3.46

Dividend

$1.89Per share, FY20263.04%Yield-0.7%5-yr growth

Capital Allocation

R&D Spend$10.7B
Capex Intensity2.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.